A5073934709- Cardiac Imaging and Diagnostics
- Advanced MRI Techniques and Applications
- Coronary Interventions and Diagnostics
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Ultrasound and Hyperthermia Applications
- Cardiovascular Disease and Adiposity
- Acute Myocardial Infarction Research
- Peripheral Artery Disease Management
- Infective Endocarditis Diagnosis and Management
- Viral Infections and Immunology Research
- Cardiomyopathy and Myosin Studies
- Blood Pressure and Hypertension Studies
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Cardiovascular Health and Disease Prevention
- Aortic Disease and Treatment Approaches
- Cerebrovascular and Carotid Artery Diseases
- Vascular Procedures and Complications
- Aortic aneurysm repair treatments
- Atrial Fibrillation Management and Outcomes
- Cardiac Structural Anomalies and Repair
- Pericarditis and Cardiac Tamponade
- Cardiac electrophysiology and arrhythmias
- Antiplatelet Therapy and Cardiovascular Diseases
Inserm
2003-2025
Université Paris Cité
2025
Assistance Publique – Hôpitaux de Paris
2025
Hôpital américain de paris
2025
Institut Cardiovasculaire Paris Sud
2016-2025
Hôpital Privé Jacques Cartier
2012-2025
Siemens (France)
2024-2025
Générale de Santé
2013-2024
Siemens Healthcare (Germany)
2024
Texas Cardiac Arrhythmia
2021
Experimental and clinical evidence suggests that cyclosporine may attenuate reperfusion injury reduce myocardial infarct size. We aimed to test whether would improve outcomes prevent adverse left ventricular remodeling.In a multicenter, double-blind, randomized trial, we assigned 970 patients with an acute anterior ST-segment elevation infarction (STEMI) who were undergoing percutaneous coronary intervention (PCI) within 12 hours after symptom onset had complete occlusion of the culprit...
Renal denervation (RDN) has been shown to lower blood pressure (BP), but its effects on cardiovascular events have only preliminarily evaluated. Time in therapeutic range (TTR) of BP is associated with events. This study sought assess the impact catheter-based RDN TTR and association outcomes GSR (Global SYMPLICITY Registry). Patients uncontrolled hypertension were enrolled treated radiofrequency RDN. Office ambulatory systolic (OSBP ASBP) measured at 3, 6, 12, 24, 36 months postprocedure...
Cardiac surgery is the reference treatment for patients with left main (LM) disease, although percutaneous coronary intervention drug-eluting stents emerging as a possible alternative. The objective of this registry was to evaluate 2-year outcome elective unprotected LM disease paclitaxel-eluting stents.A total 291 were prospectively included from 4 centers. Acute myocardial infarction and cardiogenic shock only exclusion criteria. Patients 69+/-11 years old, 29% diabetic, 25% had 3-vessel...
PurposeTo evaluate endovascular repair of type II and III thoracoabdominal aortic aneurysms (TAAA) using the Multilayer Flow Modulator (MFM) in patients with contraindications for open surgery fenestrated stent-grafts. MethodsIn this prospective, multicenter, nonrandomized trial (EudraCT registration: 2009-013678-42; ClinicalTrials.gov identifier NCT01756911), 23 (19 men; mean age 75.8 years) Crawford (43.5%) (56.5%) TAAA (mean diameter 6.5 cm) were treated MFM between April 2010 February...
Morphine is commonly used to treat chest pain during myocardial infarction, but its effect on cardiovascular outcome has never been directly evaluated. The aim of this study was examine the and safety morphine in patients with acute anterior ST-segment elevation infarction followed up for 1 year.We database CIRCUS (Does Cyclosporine Improve Outcome ST Elevation Myocardial Infarction Patients) trial, which included 969 admitted primary percutaneous coronary intervention. Two groups were...
The natural history of acute myocarditis (AM) remains partially unknown and predictors outcome are debated. We sought to assess the impact various cardiac magnetic resonance (CMR) parameters on early long-term prognosis in a population patients with AM.In two-center longitudinal study, we included consecutive diagnosis AM based CMR without hemodynamic compromise. primary endpoint was occurrence an event phase (≤15 days). Secondary endpoints were major adverse events (MACE) recurrence during...
A cardiac MRI model incorporating the ischemic late gadolinium enhancement (LGE) parameters of extent, transmurality, location, and midwall LGE significantly outperformed traditional risk factors in predicting all-cause mortality participants with cardiomyopathy.
Background Multimodality imaging is essential for personalized prognostic stratification in suspected coronary artery disease (CAD). Machine learning (ML) methods can help address this complexity by incorporating a broader spectrum of variables. Purpose To investigate the performance an ML model that uses both stress cardiac MRI and CT angiography (CCTA) data to predict major adverse cardiovascular events (MACE) patients with newly diagnosed CAD. Materials Methods This retrospective study...
Abstract Introduction The presence and extent of late gadolinium enhancement (LGE) assessed by cardiac magnetic resonance imaging (CMR) are strong prognosticators death in patients with non-ischaemic dilated cardiomyopathy (DCM), defined as left ventricular (LV) dilation ejection fraction (LVEF)<50%. Although the current guidelines concept "isolated LV dilation" (ILVD) preserved LVEF≥ 50%, prognostic value "LGE granularity" is not established this population. Purpose To assess...
Abstract Background Although the presence and extent of ischaemic late gadolinium enhancement (LGE) as assessed by cardiovascular magnetic resonance (CMR) have emerged robust predictors outcomes in patients with cardiomyopathy (ICM), prognostic significance non-ischaemic LGE is not well established. Objective To assess impact a large cohort ICM reduced left ventricular ejection fraction (LVEF) undergoing CMR for myocardial viability. Methods Between 2008 2022, all consecutive referred...
To evaluate midterm outcomes of endovascular repair types II and III thoracoabdominal aortic aneurysms (TAAA) using the Multilayer Flow Modulator (MFM) in patients unsuitable for open surgery or fenestrated stent-grafts.In prospective, multicenter, nonrandomized STRATO trial (EudraCT registration: 2009-013678-42; ClinicalTrials.gov identifier NCT01756911), 23 (mean age 75.8 years; 19 men) with Crawford type TAAA diameter 6.5 cm) were implanted between April 2010 February 2011. Outcomes...